Pub Date : 2023-09-01DOI: 10.3899/jrheum.2022-0325
Emma Rubenstein, C. Maldini, A. Vaglio, F. Bello, J. Bremer, F. Moosig, P. Bottero, Alberto Pesci, R. Sinico, J. Grosskreutz, Claudia Feder, D. Saadoun, Giorgio Trivioli, F. Maritati, B. Rewerska, W. Szczeklik, P. Fraticelli, Giuseppe Guida, G. Gregorini, G. Moroncini, B. Hellmich, J. Zwerina, Matthieu Resche-Rigon, G. Emmi, T. Neumann, A. Mahr
OBJECTIVE Previous studies suggested that distinct phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA) could be determined by presence or absence of antineutrophil cytoplasmic antibodies (ANCA), reflecting predominant vasculitic or eosinophilic processes, respectively. This study explored whether ANCA-based clusters or other clusters can be identified in EGPA. METHODS This study used standardized data of 15 European centers for patients with EGPA fulfilling widely accepted classification criteria. We used multiple correspondence analysis, hierarchical cluster analysis, and a decision tree model. The main model included 10 clinical variables (musculoskeletal, mucocutaneous, ophthalmological, ENT, cardiovascular, pulmonary, gastrointestinal, renal, central or peripheral neurological involvement); a second model also included ANCA results. RESULTS The analyses included 489 patients diagnosed in 1984-2015. ANCA were detected in 37.2% of patients, mostly P-ANCA (85.4%) and/or anti-myeloperoxidase (87.0%). Compared with ANCA-negative patients, those with ANCA had more renal (P<0.001) and peripheral neurological involvement (P=0.04), fewer cardiovascular signs (P<0.001) and fewer biopsies with eosinophilic tissue infiltrates (P=0.001). The cluster analyses generated four (model without ANCA) and five clusters (model with ANCA). Both models identified three identical clusters of 34, 39 and 40 patients according to the presence or absence of ENT, CNS and ophthalmological involvement. Peripheral neurological and cardiovascular involvement were not predictive characteristics. CONCLUSION Although reinforcing the known association of ANCA status with clinical manifestations, cluster analysis does not support a complete separation of EGPA in ANCA-positive and -negative subsets. Collectively, these data indicate that EGPA should be regarded as a phenotypic spectrum rather than a dichotomous disease.
{"title":"Cluster Analysis To Explore Clinical Subphenotypes Of Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss).","authors":"Emma Rubenstein, C. Maldini, A. Vaglio, F. Bello, J. Bremer, F. Moosig, P. Bottero, Alberto Pesci, R. Sinico, J. Grosskreutz, Claudia Feder, D. Saadoun, Giorgio Trivioli, F. Maritati, B. Rewerska, W. Szczeklik, P. Fraticelli, Giuseppe Guida, G. Gregorini, G. Moroncini, B. Hellmich, J. Zwerina, Matthieu Resche-Rigon, G. Emmi, T. Neumann, A. Mahr","doi":"10.3899/jrheum.2022-0325","DOIUrl":"https://doi.org/10.3899/jrheum.2022-0325","url":null,"abstract":"OBJECTIVE\u0000Previous studies suggested that distinct phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA) could be determined by presence or absence of antineutrophil cytoplasmic antibodies (ANCA), reflecting predominant vasculitic or eosinophilic processes, respectively. This study explored whether ANCA-based clusters or other clusters can be identified in EGPA.\u0000\u0000\u0000METHODS\u0000This study used standardized data of 15 European centers for patients with EGPA fulfilling widely accepted classification criteria. We used multiple correspondence analysis, hierarchical cluster analysis, and a decision tree model. The main model included 10 clinical variables (musculoskeletal, mucocutaneous, ophthalmological, ENT, cardiovascular, pulmonary, gastrointestinal, renal, central or peripheral neurological involvement); a second model also included ANCA results.\u0000\u0000\u0000RESULTS\u0000The analyses included 489 patients diagnosed in 1984-2015. ANCA were detected in 37.2% of patients, mostly P-ANCA (85.4%) and/or anti-myeloperoxidase (87.0%). Compared with ANCA-negative patients, those with ANCA had more renal (P<0.001) and peripheral neurological involvement (P=0.04), fewer cardiovascular signs (P<0.001) and fewer biopsies with eosinophilic tissue infiltrates (P=0.001). The cluster analyses generated four (model without ANCA) and five clusters (model with ANCA). Both models identified three identical clusters of 34, 39 and 40 patients according to the presence or absence of ENT, CNS and ophthalmological involvement. Peripheral neurological and cardiovascular involvement were not predictive characteristics.\u0000\u0000\u0000CONCLUSION\u0000Although reinforcing the known association of ANCA status with clinical manifestations, cluster analysis does not support a complete separation of EGPA in ANCA-positive and -negative subsets. Collectively, these data indicate that EGPA should be regarded as a phenotypic spectrum rather than a dichotomous disease.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76588458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-05DOI: 10.1101/2022.10.03.22280351
Eveline Y. Wu, M. Oliver, Joshua Scheck, S. Lapidus, U. Akca, S. Yasin, S. Stern, A. Insalaco, M. Pardeo, Gabriele Simonini, E. Marrani, Xing Wang, Bin Huang, L. Kovalick, Natalie Rosenwasser, Gabriel Casselman, Adriel Liau, Yurong Shao, Claire Yang, D. M. Mosa, Lori B. Tucker, H. Girschick, R. Laxer, J. Akikusa, C. Hedrich, K. Onel, F. Dedeoğlu, M. Twilt, P. Ferguson, Seza Ozen, Yongdong Zhao
Objective Prospective comparative effectiveness research (CER) in chronic nonbacterial osteomyelitis (CNO) is lacking. Our objectives were to (1) determine the use and safety of each consensus treatment plan (CTP) regimen for CNO, (2) assess the feasibility of using the Chronic Nonbacterial Osteomyelitis International Registry (CHOIR) data for CER, and (3) develop and validate a CNO clinical disease activity score (CDAS) using CHOIR. Methods Consenting children or young adults with CNO were enrolled into CHOIR. Demographic, clinical, and imaging data were prospectively collected. The CNO CDAS was developed through a Delphi survey and nominal group technique. External validation surveys were administered to CHOIR participants. Results One hundred forty (78.2%) CHOIR participants enrolled between August 2018 and September 2020 received at least 1 CTP regimen. Baseline characteristics from different CTP groups were well matched. Patient pain, patient global assessment, and clinical CNO lesion count were key variables included in the CNO CDAS. The CDAS showed a strong correlation with patient/parent report of difficulty using a limb, back, or jaw and patient/parent report of disease severity, but a weak correlation with patient/parent report of fatigue, sadness, and worry. The change in CDAS was significant in patients reporting disease worsening or improvement (P < 0.001). The CDAS significantly decreased after initiating second-line treatments from median 12.0 (IQR 8.0-15.5) to 5.0 (IQR 3.0-12.0; P = 0.002). Although second-line treatments were well tolerated, psoriasis was the most common adverse event. Conclusion The CNO CDAS was developed and validated for disease monitoring and assessment of treatment effectiveness. CHOIR provided a comprehensive framework for future CER.
{"title":"Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis","authors":"Eveline Y. Wu, M. Oliver, Joshua Scheck, S. Lapidus, U. Akca, S. Yasin, S. Stern, A. Insalaco, M. Pardeo, Gabriele Simonini, E. Marrani, Xing Wang, Bin Huang, L. Kovalick, Natalie Rosenwasser, Gabriel Casselman, Adriel Liau, Yurong Shao, Claire Yang, D. M. Mosa, Lori B. Tucker, H. Girschick, R. Laxer, J. Akikusa, C. Hedrich, K. Onel, F. Dedeoğlu, M. Twilt, P. Ferguson, Seza Ozen, Yongdong Zhao","doi":"10.1101/2022.10.03.22280351","DOIUrl":"https://doi.org/10.1101/2022.10.03.22280351","url":null,"abstract":"Objective Prospective comparative effectiveness research (CER) in chronic nonbacterial osteomyelitis (CNO) is lacking. Our objectives were to (1) determine the use and safety of each consensus treatment plan (CTP) regimen for CNO, (2) assess the feasibility of using the Chronic Nonbacterial Osteomyelitis International Registry (CHOIR) data for CER, and (3) develop and validate a CNO clinical disease activity score (CDAS) using CHOIR. Methods Consenting children or young adults with CNO were enrolled into CHOIR. Demographic, clinical, and imaging data were prospectively collected. The CNO CDAS was developed through a Delphi survey and nominal group technique. External validation surveys were administered to CHOIR participants. Results One hundred forty (78.2%) CHOIR participants enrolled between August 2018 and September 2020 received at least 1 CTP regimen. Baseline characteristics from different CTP groups were well matched. Patient pain, patient global assessment, and clinical CNO lesion count were key variables included in the CNO CDAS. The CDAS showed a strong correlation with patient/parent report of difficulty using a limb, back, or jaw and patient/parent report of disease severity, but a weak correlation with patient/parent report of fatigue, sadness, and worry. The change in CDAS was significant in patients reporting disease worsening or improvement (P < 0.001). The CDAS significantly decreased after initiating second-line treatments from median 12.0 (IQR 8.0-15.5) to 5.0 (IQR 3.0-12.0; P = 0.002). Although second-line treatments were well tolerated, psoriasis was the most common adverse event. Conclusion The CNO CDAS was developed and validated for disease monitoring and assessment of treatment effectiveness. CHOIR provided a comprehensive framework for future CER.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"3 1","pages":"1333 - 1340"},"PeriodicalIF":0.0,"publicationDate":"2022-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78323006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I read the paper by Deng et al,1 in which the authors conducted a metaanalysis to evaluate whether febuxostat use increased the risk of developing cardiovascular (CV) events, cardiac death, and all-cause mortality. The adjusted relative risk (RR) of febuxostat use for all-cause mortality was 0.87 (95% CI 0.57-1.32).
我阅读了Deng等人的论文，其中作者进行了一项荟萃分析，以评估非布司他是否会增加发生心血管事件、心源性死亡和全因死亡率的风险。非布司他对全因死亡率的校正相对危险度(RR)为0.87 (95% CI 0.57-1.32)。
{"title":"Febuxostat Use and Safety in Patients With Hyperuricemia","authors":"T. Kawada","doi":"10.3899/jrheum.220147","DOIUrl":"https://doi.org/10.3899/jrheum.220147","url":null,"abstract":"I read the paper by Deng et al,1 in which the authors conducted a metaanalysis to evaluate whether febuxostat use increased the risk of developing cardiovascular (CV) events, cardiac death, and all-cause mortality. The adjusted relative risk (RR) of febuxostat use for all-cause mortality was 0.87 (95% CI 0.57-1.32).","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"67 1","pages":"1180 - 1180"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78087288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We sincerely appreciate Dr. Kawada's comments in response to our metaanalysis.1 We agree with most of these opinions and would like to clarify our views here.
我们真诚地感谢Kawada博士对我们荟萃分析的评论我们同意大部分观点，在此澄清我们的观点。
{"title":"Dr. Deng et al reply","authors":"Hao Deng, X. Yang, H. Jin","doi":"10.3899/jrheum.220179","DOIUrl":"https://doi.org/10.3899/jrheum.220179","url":null,"abstract":"We sincerely appreciate Dr. Kawada's comments in response to our metaanalysis.1 We agree with most of these opinions and would like to clarify our views here.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"85 1","pages":"1180 - 1180"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88534387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Understanding adverse events (AEs) of disease-modifying antirheumatic drugs (DMARDs) for treatment of rheumatoid arthritis (RA) is critical to both patients and clinicians. AEs-"side effects" from the patient perspective-contribute significantly to patients' disease experience by interfering with activities of daily living and quality of life (QOL).1.
{"title":"The Patient Experience of Drug Side Effects in Rheumatoid Arthritis: Intriguing Data From an Exploratory Online Survey","authors":"John M. Davis","doi":"10.3899/jrheum.220412","DOIUrl":"https://doi.org/10.3899/jrheum.220412","url":null,"abstract":"Understanding adverse events (AEs) of disease-modifying antirheumatic drugs (DMARDs) for treatment of rheumatoid arthritis (RA) is critical to both patients and clinicians. AEs-\"side effects\" from the patient perspective-contribute significantly to patients' disease experience by interfering with activities of daily living and quality of life (QOL).1.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"5 1","pages":"967 - 970"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88370109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Hwang, Sanghoon Lee, J. Shin, Ki Woong Kim, H. Gong
Objective Index-to-ring finger ratio (IRFR) has been reported to be associated with joint osteoarthritis (OA). We aimed to evaluate the association between IRFR and trapeziometacarpal joint (TMCJ) OA in an elderly Korean population. Methods A population-based sample included 604 participants with a mean age of 74.8 years. IRFR was radiographically measured by the ratio of the length of the right second to fourth phalangeal bones (“phalangeal IRFR”) and metacarpal bones (“metacarpal IRFR”), and was visually classified as either type 1 (index finger longer than or equal to ring finger) or type 2 (index finger shorter than ring finger). Odds ratios (ORs) for the presence of OA (Kellgren-Lawrence [KL] grade > 1) and for severe OA (KL grade > 2) were analyzed using logistic regression. Results The phalangeal IRFR averaged 91.3%, the metacarpal IRFR 116.7%, and 304 out of 604 participants (50.3%) had type 2 IRFR. We found TMCJ OA in 112 participants (18.5%), and severe TMCJ OA in 33 participants (5.5%). Presence of TMCJ OA was significantly associated with age (OR 1.04; 95% CI 1.01-1.06) and metacarpal IRFR (OR 0.94; 95% CI 0.88-0.99), and severe TMCJ OA with age (OR 1.08; 95% CI 1.03-1.12) and type 2 IRFR (OR 3.07; 95% CI 1.13-8.33). Conclusion Radiographic IRFR, specifically metacarpal IRFR, was associated with the presence of TMCJ OA, and visual IRFR with severe TMCJ OA in both elderly Korean men and women. The results of this study suggest that IRFR might serve as an easily measurable biomarker to identify patients vulnerable to TMCJ OA.
目的研究指指比(IRFR)与关节骨性关节炎(OA)的关系。我们的目的是评估韩国老年人IRFR与TMCJ骨性关节炎之间的关系。方法以人群为基础的样本包括604名参与者，平均年龄为74.8岁。IRFR通过放射学测量右手第二指骨与第四指骨(“指骨IRFR”)和掌骨(“掌骨IRFR”)的长度之比，并在视觉上分为1型(食指长于或等于无名指)或2型(食指短于无名指)。采用logistic回归分析存在OA (Kellgren-Lawrence [KL]分级> 1)和严重OA (KL分级> 2)的优势比(ORs)。结果604例患者中，指骨IRFR平均为91.3%，掌骨IRFR平均为116.7%，304例(50.3%)为2型IRFR。我们发现112名参与者(18.5%)患有TMCJ性关节炎，33名参与者(5.5%)患有重度TMCJ性关节炎。tmcjoa的存在与年龄显著相关(OR 1.04;95% CI 1.01-1.06)和掌骨IRFR (OR 0.94;95% CI 0.88-0.99)，严重TMCJ关节炎随年龄增长(OR 1.08;95% CI 1.03-1.12)和2型IRFR (OR 3.07;95% ci 1.13-8.33)。结论影像学IRFR，特别是掌骨IRFR，与TMCJ型骨性关节炎的存在有关，在韩国老年男性和女性中，视觉IRFR与严重TMCJ型骨性关节炎有关。本研究结果表明，IRFR可能作为一种易于测量的生物标志物，用于识别易患TMCJ OA的患者。
{"title":"The Association of Index-to-Ring Finger Ratio With Trapeziometacarpal Joint Osteoarthritis in an Elderly Korean Population","authors":"J. Hwang, Sanghoon Lee, J. Shin, Ki Woong Kim, H. Gong","doi":"10.3899/jrheum.211355","DOIUrl":"https://doi.org/10.3899/jrheum.211355","url":null,"abstract":"Objective Index-to-ring finger ratio (IRFR) has been reported to be associated with joint osteoarthritis (OA). We aimed to evaluate the association between IRFR and trapeziometacarpal joint (TMCJ) OA in an elderly Korean population. Methods A population-based sample included 604 participants with a mean age of 74.8 years. IRFR was radiographically measured by the ratio of the length of the right second to fourth phalangeal bones (“phalangeal IRFR”) and metacarpal bones (“metacarpal IRFR”), and was visually classified as either type 1 (index finger longer than or equal to ring finger) or type 2 (index finger shorter than ring finger). Odds ratios (ORs) for the presence of OA (Kellgren-Lawrence [KL] grade > 1) and for severe OA (KL grade > 2) were analyzed using logistic regression. Results The phalangeal IRFR averaged 91.3%, the metacarpal IRFR 116.7%, and 304 out of 604 participants (50.3%) had type 2 IRFR. We found TMCJ OA in 112 participants (18.5%), and severe TMCJ OA in 33 participants (5.5%). Presence of TMCJ OA was significantly associated with age (OR 1.04; 95% CI 1.01-1.06) and metacarpal IRFR (OR 0.94; 95% CI 0.88-0.99), and severe TMCJ OA with age (OR 1.08; 95% CI 1.03-1.12) and type 2 IRFR (OR 3.07; 95% CI 1.13-8.33). Conclusion Radiographic IRFR, specifically metacarpal IRFR, was associated with the presence of TMCJ OA, and visual IRFR with severe TMCJ OA in both elderly Korean men and women. The results of this study suggest that IRFR might serve as an easily measurable biomarker to identify patients vulnerable to TMCJ OA.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"53 1","pages":"1152 - 1157"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90201892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Glintborg, D. Jensen, L. Terslev, O. Hendricks, M. Østergaard, S. Rasmussen, M. P. Jensen, T. Adelsten, A. Colic, K. Danebod, M. Kildemand, A. Loft, H. Munk, J. K. Pedersen, R. Østgård, C. M. Sørensen, N. Krogh, J. Agerbo, C. Ziegler, M. Hetland
Objective To explore anxiety and self-isolation in patients with inflammatory rheumatic disease (IRD)15 months into the coronavirus disease 2019 (COVID-19) pandemic, including attitudes toward and effects of SARS-CoV-2 vaccination. Methods A nationwide online survey was conducted at 3 timepoints: May 2020, November 2020, and May 2021. Patients with IRD followed in the Danish Rheumatology Quality Registry (DANBIO) were asked about the effects of the pandemic, including SARS-CoV-2 infection and their behavior, anxiety, and concerns. The May 2021 survey included attitudes toward SARS-CoV-2 and influenza vaccination. Characteristics associated with self-isolation in May 2021 were explored with adjusted logistic regression analyses that included patient characteristics and SARS-CoV-2 vaccination status. Results Respondents to surveys 1, 2, and 3 included 12,789; 14,755; and 13,921 patients, respectively; 64% had rheumatoid arthritis and 63% were female. Anxiety and concerns were highest in May 2020 and decreased to stable levels in November 2020 and May 2021; 86%, 50%, and 52% of respondents reported self-isolation, respectively. In May 2021, 4% of respondents self-reported previous SARS-CoV-2 infection. The SARS-CoV-2 vaccine acceptance rate was 86%, and the proportion of patients vaccinated against influenza had increased from 50% in winter 2019-2020 to 64% in winter 2020-2021. The proportion of patients with anxiety appeared similar among those vaccinated and unvaccinated against SARS-CoV-2. In multivariable analyses, being unvaccinated, female gender, receiving biologic drugs, and poor quality of life were independently associated with self-isolation. Conclusion Levels of anxiety and self-isolation decreased after the initial lockdown period in patients with IRD. Half of the patients reported self-isolation in May 2021, a phase that included widespread reopening of society and large-scale vaccination. The lack of prepandemic data prevented a full understanding of the long-term effects of the pandemic on anxiety and self-isolation in patients with IRD.
{"title":"Long-term Behavioral Changes During the COVID-19 Pandemic and Impact of Vaccination in Patients With Inflammatory Rheumatic Diseases","authors":"B. Glintborg, D. Jensen, L. Terslev, O. Hendricks, M. Østergaard, S. Rasmussen, M. P. Jensen, T. Adelsten, A. Colic, K. Danebod, M. Kildemand, A. Loft, H. Munk, J. K. Pedersen, R. Østgård, C. M. Sørensen, N. Krogh, J. Agerbo, C. Ziegler, M. Hetland","doi":"10.3899/jrheum.211280","DOIUrl":"https://doi.org/10.3899/jrheum.211280","url":null,"abstract":"Objective To explore anxiety and self-isolation in patients with inflammatory rheumatic disease (IRD)15 months into the coronavirus disease 2019 (COVID-19) pandemic, including attitudes toward and effects of SARS-CoV-2 vaccination. Methods A nationwide online survey was conducted at 3 timepoints: May 2020, November 2020, and May 2021. Patients with IRD followed in the Danish Rheumatology Quality Registry (DANBIO) were asked about the effects of the pandemic, including SARS-CoV-2 infection and their behavior, anxiety, and concerns. The May 2021 survey included attitudes toward SARS-CoV-2 and influenza vaccination. Characteristics associated with self-isolation in May 2021 were explored with adjusted logistic regression analyses that included patient characteristics and SARS-CoV-2 vaccination status. Results Respondents to surveys 1, 2, and 3 included 12,789; 14,755; and 13,921 patients, respectively; 64% had rheumatoid arthritis and 63% were female. Anxiety and concerns were highest in May 2020 and decreased to stable levels in November 2020 and May 2021; 86%, 50%, and 52% of respondents reported self-isolation, respectively. In May 2021, 4% of respondents self-reported previous SARS-CoV-2 infection. The SARS-CoV-2 vaccine acceptance rate was 86%, and the proportion of patients vaccinated against influenza had increased from 50% in winter 2019-2020 to 64% in winter 2020-2021. The proportion of patients with anxiety appeared similar among those vaccinated and unvaccinated against SARS-CoV-2. In multivariable analyses, being unvaccinated, female gender, receiving biologic drugs, and poor quality of life were independently associated with self-isolation. Conclusion Levels of anxiety and self-isolation decreased after the initial lockdown period in patients with IRD. Half of the patients reported self-isolation in May 2021, a phase that included widespread reopening of society and large-scale vaccination. The lack of prepandemic data prevented a full understanding of the long-term effects of the pandemic on anxiety and self-isolation in patients with IRD.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"35 1","pages":"1163 - 1172"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81540457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Le Ralle, C. Daste, F. Rannou, L. Kwakkenbos, M. Carrier, M. Lefèvre-Colau, A. Roren, B. Thombs, L. Mouthon, C. Nguyen
Objective People with systemic sclerosis (SSc) often report substantial burden from appearance changes. We aimed to estimate the patient acceptable symptom state (PASS) for burden from appearance changes in people with SSc. Methods We conducted a secondary analysis of the SCISCIF II study, a cross-sectional survey of 113 patients with SSc from France enrolled in the Scleroderma Patient-centered Intervention Network Cohort. Burden from appearance changes was assessed with a self-administered numeric rating scale (0, no burden to 10, maximal burden). Acceptability of the symptom state was assessed with a specific anchoring question. Participants who answered yes were in the group of patients who considered their symptom state as acceptable. The PASS for the burden from appearance changes was estimated with the 75th percentile method. Results Assessments of burden from appearance changes and answers to the anchoring question were available in 82/113 (73%) participants from the SCISCIF II study. Median age was 55 (IQR 24) years, mean disease duration 9.6 (SD 6.5) years and 32/80 (40%) participants had diffuse cutaneous SSc. The PASS estimate for the burden from appearance changes was 4.8 (95% CI 1.0-7.0) of 10 points. Conclusion Our study provides a PASS estimate for burden from appearance changes. Our estimate could serve as a binary response criterion to assess the efficacy of treatments targeting burden from appearance changes.
目的:系统性硬化症(SSc)患者经常报告外观变化带来的沉重负担。我们的目的是评估SSc患者外观变化带来的负担的患者可接受症状状态(PASS)。方法:我们对SCISCIF II研究进行了二次分析，这是一项来自法国的113例SSc患者的横断面调查，纳入硬皮病患者为中心的干预网络队列。采用自我管理的数字评分量表(0，无负担至10，最大负担)评估外观变化带来的负担。用一个特定的锚定问题来评估症状状态的可接受性。回答“是”的参与者属于认为自己的症状状态可以接受的患者群体。外观变化负担的PASS用75百分位法估计。结果:在SCISCIF II研究中，82/113(73%)参与者可获得外观变化带来的负担评估和锚定问题的答案。中位年龄为55岁(IQR 24)岁，平均病程9.6年(SD 6.5)年，32/80(40%)的参与者患有弥漫性皮肤SSc。外观变化造成的负担的PASS估计为4.8 (95% CI 1.0-7.0)，满分为10分。结论本研究提供了对外观变化负担的PASS估计。我们的估计可以作为一个二元反应标准来评估针对外观改变负担的治疗效果。
{"title":"Patient Acceptable Symptom State for Burden From Appearance Changes in People With Systemic Sclerosis: A Cross-sectional Survey","authors":"M. Le Ralle, C. Daste, F. Rannou, L. Kwakkenbos, M. Carrier, M. Lefèvre-Colau, A. Roren, B. Thombs, L. Mouthon, C. Nguyen","doi":"10.3899/jrheum.210889","DOIUrl":"https://doi.org/10.3899/jrheum.210889","url":null,"abstract":"Objective People with systemic sclerosis (SSc) often report substantial burden from appearance changes. We aimed to estimate the patient acceptable symptom state (PASS) for burden from appearance changes in people with SSc. Methods We conducted a secondary analysis of the SCISCIF II study, a cross-sectional survey of 113 patients with SSc from France enrolled in the Scleroderma Patient-centered Intervention Network Cohort. Burden from appearance changes was assessed with a self-administered numeric rating scale (0, no burden to 10, maximal burden). Acceptability of the symptom state was assessed with a specific anchoring question. Participants who answered yes were in the group of patients who considered their symptom state as acceptable. The PASS for the burden from appearance changes was estimated with the 75th percentile method. Results Assessments of burden from appearance changes and answers to the anchoring question were available in 82/113 (73%) participants from the SCISCIF II study. Median age was 55 (IQR 24) years, mean disease duration 9.6 (SD 6.5) years and 32/80 (40%) participants had diffuse cutaneous SSc. The PASS estimate for the burden from appearance changes was 4.8 (95% CI 1.0-7.0) of 10 points. Conclusion Our study provides a PASS estimate for burden from appearance changes. Our estimate could serve as a binary response criterion to assess the efficacy of treatments targeting burden from appearance changes.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"7 1","pages":"903 - 907"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84143063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that affects one-third of patients with psoriasis (PsO). PsA is a relatively common condition in rheumatology clinics. In fact, the prevalence of PsA increased to approximately 0.6% of the general population in a recent epidemiological study carried out in Spain.1.
{"title":"Active Disease in Psoriatic Arthritis: An Assessment of Spondyloarthritis International Society Health Index (ASAS-HI)–based Analysis","authors":"R. Queiró, I. Morante, I. Braña","doi":"10.3899/jrheum.210887","DOIUrl":"https://doi.org/10.3899/jrheum.210887","url":null,"abstract":"Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that affects one-third of patients with psoriasis (PsO). PsA is a relatively common condition in rheumatology clinics. In fact, the prevalence of PsA increased to approximately 0.6% of the general population in a recent epidemiological study carried out in Spain.1.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"78 1","pages":"961 - 963"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88562125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Unfortunately, not much is certain in systemic autoimmune rheumatic diseases (SARDs). People with a SARD such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are dealing with a chronic, inflammatory, and often unpredictable autoimmune condition that might cause them to experience illness-related uncertainty.1,2.
{"title":"Fear of the Unknown: Can We Help Individuals With a Systemic Autoimmune Rheumatic Disease Deal With Uncertainty?","authors":"G. Simons, M. Falahee","doi":"10.3899/jrheum.220502","DOIUrl":"https://doi.org/10.3899/jrheum.220502","url":null,"abstract":"Unfortunately, not much is certain in systemic autoimmune rheumatic diseases (SARDs). People with a SARD such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are dealing with a chronic, inflammatory, and often unpredictable autoimmune condition that might cause them to experience illness-related uncertainty.1,2.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"2 1","pages":"977 - 979"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75403771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：